Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains challenging to treat owing to the limited response to available therapies. However, recent advances in understanding of disease mechanisms have led to the discovery of novel potential therapeutic targets and drug candidates. In addition to regulatory approval for the IL-4Ra inhibitor dupilumab, the anti-IL-13 inhibitor tralokinumab and the JAK1/2 inhibitor baricitinib in Europe, there are now more than 70 new compounds in development. This Review assesses the various strategies and novel agents currently being investigated for AD and highlights the potential for a precision medicine approach to enable prevention and more effective long-term control of this complex disease.

特应性皮炎 (AD) 是一种常见的慢性炎症性皮肤病，具有复杂的病理生理学特征，是多种临床表型的基础。由于对可用疗法的反应有限，AD 的治疗仍然具有挑战性。然而，最近在对疾病机制的理解方面取得的进展导致发现了新的潜在治疗靶点和候选药物。除了在欧洲获得监管部门批准的 IL-4Ra 抑制剂 dupilumab、抗 IL-13 抑制剂 tralokinumab 和 JAK1/2 抑制剂 baricitinib 外，目前还有 70 多种新化合物正在开发中。本综述评估了目前正在研究的 AD 的各种策略和新药，并强调了精准医学方法的潜力，以实现对这种复杂疾病的预防和更有效的长期控制。